Jiangxi Fushine Pharmaceutical Faces Increased Risk Amid Mixed Financial Performance Signals

Jiangxi Fushine Pharmaceutical Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation grade, which has transitioned to a classification indicating a higher level of risk. The adjustment comes in light of various financial metrics that suggest a complex performance landscape. The company has reported a notable growth in net profit, with a significant increase of 692.07% in March 2026, alongside positive results for the last two consecutive quarters. However, long-term trends reveal challenges, including a decline in net sales at an annual rate of -2.90% and a decrease in operating profit by -34.60% over the past five years. The return on capital employed (ROCE) has averaged 4.17%, indicating weak long-term fundamental strength. Despite these challenges, Jiangxi Fushine has demonstrated market-beating performance, generating a return of 135.31% over the past year and outperforming the China Shanghai Composite index in various time frames. The stock's technical indicators present a mixed picture, with some metrics showing bullish trends while others indicate a more cautious outlook. For those interested in further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.